EGF and non-small cell lung carcinoma: These findings emphasize the impact of the immune status on the clinical evolution of CIMAvax-EGF vaccinated NSCLC patients and validate the usefulness of late-stage differentiated CD8+ T cells as predictive biomarkers for the CIMAvax-EGF efficacy (36).